FIT Biotech Oy Extending Subscription Period of its Offering – FIT Biotech

Reports and Releases

FIT Biotech Oy Extending Subscription Period of its Offering

COMPANY RELEASE 16 JUNE 2015 at 23.00

FIT Biotech Oy Extending Subscription Period of its Offering
 

NOT TO BE PUBLISHED OR DISTRIBUTED IN AUSTRALIA, SOUTH AFRICA, HONG KONG, JAPAN, CANADA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL.

In accordance with the terms and conditions of the offering, the Board of Directors of FIT Biotech Oy (the "Company") has today decided to extend the subscription period of the offering related to the listing of the Company to 16:30 (Finnish time) on  25 June 2015. The subscription period is being extended in the same manner for the institutional offering, public offering and conversion offering (jointly "Offering").

New Timetable for the Offering

End of subscription period 25 June 2015 at 16:30
Result of offering published on or about 29 June 2015
Offer shares entered into book-entry accounts on or about 30 June 2015
Trading in shares to be listed on First North expected to begin on or about 1 July 2015

More information on the Offering is available in the Finnish-language listing prospectus available on the website of the subscription place of the Offering, FIM Sijoituspalvelut Oy at www.fim.com/FIT and on the Company's website at www.fitbiotech.com/investors.

The Company's financial advisor and the Company's certified advisor in accordance with the Rules of First North is Translink Corporate Finance Oy.  The Company's legal advisor is Castrén & Snellman Attorneys Ltd.

Additional information:

CEO Kalevi Reijonen, FIT Biotech Oy
Email: kalevi.reijonen@fitbiotech.com
Phone: +358 40 843 5695

Tina Nyfors, Board Member, FIT Biotech Oy
Phone: +358 04 684 9502

DISCLAIMER

The information contained herein is not for publication or distribution, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, South Africa or the United States. These written materials do not constitute an offer of securities for sale in the United States, nor may the securities be offered or sold in the United States absent registration or an exemption from registration as provided in the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder or unless an exemption to the registration obligation has been granted. No part of this Offering will be registered in the United States nor will the securities be offered to the public in the United States.

In certain states, the issue, use and/or sale of securities is subject to special legal or legislative restrictions. The Company or Translink Corporate Finance Oy assume no responsibility in the event there is a violation by any person of such restrictions.

The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. Investors must neither accept any offer for, nor acquire, any securities to which this document refers, unless they do so on the basis of the information contained in the applicable prospectus published or offering circular distributed by the Company.

The Company has not given authorisation for offering the securities to the public in any other member state of the European Economic Area than Finland. Save for Finland, measures for offering the securities to the public have not been and will not be taken in any member state of the European Economic Area having implemented the Prospectus Directive (each a "Relevant Member State") in a way that would require the publication of a prospectus in the Relevant Member State. As a consequence, the securities can only be offered in the Relevant Member States to (a) legal persons that are qualified investors as defined in the Prospectus Directive or (b) in any other situation mentioned in Article 3(2) of the Prospectus Directive. In this paragraph, the expression 'offer securities to the public' means communication by any means presenting sufficient information on the terms of the offer and the securities to be offered, so as to enable an investor to decide to use, purchase or subscribe to these securities, as the expression may vary due to the implementation measures taken in the Member State. The expression 'Prospectus Directive' refers to Directive 2003/71/EC (as amended, including the 2010 Amending Directive, to the extent that it has been implemented in the Relevant Member State), and it includes all relevant implementation measures in the Relevant Member State, and the expression '2010 Amending Directive' refers to Directive 2010/73/EC.

The information presented herein is targeted only at (i) persons outside the United Kingdom or (ii) persons with professional investment experience in the manner referred to in Article 19(5) of the United Kingdom Financial Services and Markets Act (Financial Promotion) Order 2005 and (iii) high net worth entities specified in Article 49(2) of the Order or other persons to which the document can be lawfully communicated (all jointly the "Relevant Persons"). Any investment activity to which this communication relates will only be available to and will only be engaged with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this document or any of its contents.

Back to list